CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 31,415 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 31,415 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total value of $786,317.45. Following the completion of the transaction, the chief executive officer owned 787,799 shares of the company’s stock, valued at $19,718,608.97. This trade represents a 3.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Trading Down 2.3%

Shares of CBLL traded down $0.58 during midday trading on Thursday, hitting $24.31. The stock had a trading volume of 262,277 shares, compared to its average volume of 346,888. The business has a 50-day simple moving average of $19.30 and a two-hundred day simple moving average of $19.16. The firm has a market cap of $932.97 million, a P/E ratio of -13.81 and a beta of 0.81. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. As a group, equities analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current year.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its stake in shares of CeriBell by 5.5% in the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after acquiring an additional 4,572 shares during the last quarter. Formula Growth Ltd. acquired a new stake in CeriBell during the second quarter valued at $603,000. Bank of America Corp DE purchased a new position in CeriBell in the second quarter valued at about $4,619,000. PDT Partners LLC purchased a new position in CeriBell in the second quarter valued at about $1,026,000. Finally, Legal & General Group Plc acquired a new position in CeriBell in the 2nd quarter worth about $53,000.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CBLL. Canaccord Genuity Group lifted their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. BTIG Research increased their price objective on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.